Neurocognitive outcome in survivors of pediatric cancer

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Purpose of Review: There are more than 11 million survivors of pediatric cancers living in the US. The largest proportion had leukemia and the group most severely impacted by their cancer and their therapies are the survivors of central nervous system (CNS) tumors. This review describes the neurocognitive outcome for these groups and outlines work aimed at understanding the pathophysiology of and approach to ameliorating neurocognitive dysfunction. RECENT FINDINGS: The impact of chemotherapy on children treated for leukemia without radiation has been elucidated and the differential impact of different radiation fields and doses among children with CNS malignancies has been described. Newer imaging techniques may predict damage earlier and animal models of chemotherapy-induced neurotoxicity may prove valuable in designing less toxic therapies or finding protective agents. Cognitive training programs, notably computerized programs that can be accessed at home, may be part of successful programs for minimizing neurotoxicity. SUMMARY: This review seeks to describe the neurocognitive consequences of cancer and its therapy among pediatric patients treated for leukemia or a CNS tumor. The consequences of therapy with and without cranial radiation are described and information on potentially valuable animal models and imaging techniques are presented. The impact of host pharmacogenomics is outlined.

Original languageEnglish (US)
Pages (from-to)27-33
Number of pages7
JournalCurrent opinion in pediatrics
Issue number1
StatePublished - Feb 1 2011


  • neurocognitive dysfunction
  • pediatric cancer
  • risk factors

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Neurocognitive outcome in survivors of pediatric cancer'. Together they form a unique fingerprint.

Cite this